Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes you are absolutely right.
Remember some investors have been worried needlessly about the promised-but-yet seen publication based on DCVax-D trial. Now they have the answer: the granted patent, which is more comprehensive, broad and protective and much more significant than one or two papers published in Lancet or NEJM.
This is all about D, which alone will be worthy of billion if the condition is right. Things have now turned out being better than promised.
Equally if not more, investors should not be worry about L. Results will be published, and the L will be approved.
Yes, but not from the standpoint of the steady short interest declines beginning in lat May. [please also note the steady decline of price for NVCR recently] this is just one indication for the literal meaning of SOON unless you also think Linda is a scammer (I bet not)
Yes by any standard, NWBIO's communication and its PR function is underpar; its treatment on retail investors is underpar, despite the fact this company has been essentially supported single-handedly by retail investors, not those few island boys and bigger investors of vulture in nature; and the list is long.
But I choose to believe besides the above, the company has worked as hard and smart as possible trying to bring DCVax-L into market, and during this painful and potentially rewarding process, there are reasons why the company has acted the way it does, and I conclude it's useless to be stuck on these answered puzzles/questions. Instead
I do think regardless the goal of the company and mine is aligned, and the interests of the company and mine is aligned, based on the highly probable outcomes of DCVax-L trial revealing positive results, and being finally approved by RAs, based on known data published alone.
So I choose to believe, bought most of my shares in the range of $0.14-0.30, bought as high as $7, average down and average up recently from $1.6s all the way to $1.1s.
Even the short, at least the one who are legal and have guts to reveal their investment know the day is ever closer. Linda should and must catch the short off guard. [my bet is not on legal short, but naked short wolfpack. Linda do it]
Short Interest
Date Short Interest % Change AVG. Daily Share Vol Days to CoverSplitNew Issue
08/31/2021 11,253,827 -7.01 1,841,933 6.11No No
08/13/2021 12,102,017 -2.29 3,440,237 3.52No No
07/30/2021 12,385,136 0.60 2,766,039 4.48No No
07/15/2021 12,310,972 -35.63 2,874,241 4.28No No
06/30/2021 19,124,021 -0.24 2,647,478 7.22No No
06/15/2021 19,169,952 -3.85 3,256,905 5.89No No
05/28/2021 19,937,340 0.73 5,231,957 3.81No No
No use of debating on why this delay and that delay, and speculate on why said this and not that, why, why, why, simply because there will always numerous and various scenarios, possibilities, let alone imaginations if one thinks hard about anything.
We know this company is not a normal one by any standard. Just relax, all the whys you ever have asked will be answered SOON!
Exactly right sukus. that's the reason I have been buying when price is low and softening, in effect I have recently been a buyer from $1.6s all the way down to $1.1s.
Because the data we all have known will never flip, and based on the trend of its subsequent followed up, the data is actually trending to our advantage as longs, and the chance the data continually trending positive is higher than its trending negative (flips)
Plus as we all know
SOC has been in a flat line in terms of patients OS at least during the life of this trial (about 15 years)
updated SAP, and endpoints from which we know it's most probably if not absolute the primary endpoint is significant......
WHO's definition of GBM which is highly favorable, and the fact
NWBIO has recently had timely SEC reports, No substantial fund raises, no distractions whatever besides the now "notorious" quiet period, such as launch a new trial, etc.
and no insiders selling
One explanation why all of a sudden from expecting report of TLD in September to including those six gigantic steps which may well be a gigantic delay strategy and tactics is the company is in a slow and painful or a procedural gigantic partnership or buyout deal.
But whatever the reason, Linda will have to report Sawston certification update, TLD/full data, and after that we will know the reason why this gigantic delay.
Believing the data will not flip is enough for me to add shares at each and every downturn
GL to you
Probably he is, and so is the man you responded to. I know you are a bear or just a swing trader (nothing wrong in and by itself though), but the question the bear and bull should all ask if still any doubt in minds is
Does data flip
the data we all known which is published https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
and its subsequent better trending update from drs Bosch and Liau.
I have been a buyer at each and every turn of long flips
Anther LONG TERM holder! At least this time around you have kept positive vibes for quite a while.
Good job! seem better than that 20% premium guys who should also be proud to beat most WS hedges.
Keep going man you are in the right track
Old news nothing new except for the word expected, it's originally published in Chinese for Chinese readers.
But the conclusion is right. DCVax-L is indeed expected to be approved.
Let's see first how better are the data evolved from the blinded data.
How do you know it's a 'fairytale' exactly, since naked shorting is illegal, a crime committed, thus-hidden, and even sometimes knowingly or unknowingly sanctioned legally by SEC by allowing MMs for carrying a balance of "undeliverables" of a mix bag forward for unlimited time in the name of able to maintain a market. And MMs trade those balances back and forth all the time. the usually healthy market is maintained by the pure sanity of MMs, which means not all MMs are dumb enough.
On the other hand, there is always much simpler village level short story.
Below is a naked short story not so sophisticated committed starring boy genius Martin Shkreli:
https://caia.org/blog/2015/12/27/denial-the-role-of-naked-shorting-in-the-fall-of-martin-shkreli
" ......
Back on the Rails
Let’s get back to the failure-to-deliver matter though. The indictment charges that on or about February 1, 2011, Shkreli took a large short position in Orexigen Therapeutics (OREX) on a brokerage account that his MSMB Capital maintained with Merrill Lynch. Shkreli had not actually located the ORX shares to borrow: that is – although the indictment doesn’t use the language – his position was naked. Further, Shkreli and MSMB falsely maintained to Merrill Lynch that it did have cover for these positions.
OREX had taken a very sharp fall in late January of that year, all the way from a high of $9.54 to a close of $1.77 on the final day of the month. It may have seemed an easy bet that the fall would continue. But it didn’t. Heading into February, the price stabilized. At the left hand edge of the stock chart at the top of this story, you’ll see the sharp drop, and then the brief plateau that came into existence precisely at the moment when Shkreli was betting it wouldn’t.
MSMB defaulted on its position, and Merrill Lynch had to take a loss of $7 million. Due to this and related developments at the same time, the value of MSMB Capital’s bank and brokerage accounts fell from $1.12 million to just $58,500 in the month of February alone. Also, MSMB stopped trading. In effect, it was done.
If the indictment is accurate – the burden of proof is of course on the prosecution and there has been no trial at which that burden could have been satisfied – this was a fateful moment for Shkreli and Greebel. They responded to this set-back with what a Freudian would surely recognize as Denial as a defense mechanism. They acted – and presented numbers for the relevant entities to the public – as if nothing of the sort had taken place.
......"
To be honest, a sane person or entity would have long covered his/her/its illegally shorted (naked short) position of nwbo, but there is always endless dumb or dumber or dumbest thing happen.
And if such a thing happens, it usually happens out of proportion.
My money is not bet on that of course, which is on science and known data in anticipation of the similar if not better data from unblinded trial. But if indeed is the case with tens of million or hundreds of millions of naked short shares, I will be out of proportionally happier.
BB genius!
When stock price has continually depreciated for three months, it's understood many investors have self injected FUD. In a matter of fact, nwbio is still worthy of about 1 billion in MC which by and in itself is a very bullish sign.
Because nwbo is an otc stock without serious money support, and it's in effect a retail stock; CEO Linda is hated by pretty much everybody, longs hate her for never ever delivering on her own schedule; shorts hate her for never ever giving in/up, so ambitious, go big or go home mantra; the sideliners hate her for suspicious of her double dealing, enriching herself but not common investors ...
But the market still believes nwbio's product DCVax-L will be ultimately a success regardless, and the market is right.
Anyone has a brain and has spent one half day of time doing own DD would realize DCVax-L trial data would be at least beating Optune's, and at least the primary endpoint would be significant. There may be ups and downs in the road of approval, but we will be definitely there.
In conclusion the data at worst would be controversial but it will demonstrate efficacy. With its pristine safety, no RAs would deny its approval.
The above is the worst case scenario for me, and I think the market agrees with me.
on the other hand, the serious money now waiting for data and uplifting to buy, Linda and her gang waiting for rewarding themselves with options at lowest price possible, and pretty much everyone except fully committed retails like myself, ... all want the share price as low as possible.
So it's clear the recent price is a strong-buy price, if not the lowest before major climb embarks.
I would recommend you use that amount of money to buy nwbo ($2.15 x 1,000,000 = $2,150,000). Buy only five minutes before market close each trading day, for $100,000 worth of nwbo stock, which can give you about 22 trading days. Starting today, you can single-handedly make nwbo stock price steady-appreciation until early September when probably the market itself would be crazy for nwbo. The continual declining of nwbo stock in recent months for a big part is because nobody has had the conviction and resolve and resource.
I don't have that kind of resource and I have already stretched enough to concentrate my investment in nwbo, more than 80% of my portfolio.
Then, there may be others who may be by coincident do the same.
By the time your otlk reaches ten dollar (4-5 baggars) nwbo may have reached 10 baggars. and It's meaningful and profitable to protect your already huge position in nwbo by doing something.
Of course I am happy too if nwbo were ever down back to dimes, you may quadruple your holding I guarantee I will increase my holding by ten fold.
Seriously why not put some resources to work to support nwbo price?
I am talking about options to be rewarded. At times in the future if some milestones are reached, they will reward them new options of a certain numbers to key employees with target price based on the then market price (usually somewhat higher than the then market price)
this my last post for today. GLTA!
[bty at 3:30pm started buying more shares. thanks]
Linda and the gang reward themselves via options based on milestone reached. So what could be milestone ahead. My rough guess:
complete data analyses and announcement of data;
manufacturing certified in UK;
Achievement of some RA designations;
Submission of BLA,
....
The most tricky part is the price of options they get rewarded. If they space out those above milestone achievement the price will substantially increase in a stair up manner, that will not what Linda and gang want.
For Linda and gang in this case, the best interets for them to have rewarded themselves options with low target price is the market price at the time of rewarding is as low as possible
So I guess in this sense it's best to achieve multiple milestones once at the same time when they end the great quietness.
Linda has been ambitious and greedy for herself (approved), and/or us investors (has yet to be approved)
Not sure what Linda has been deliberating but it must be a golden baby. If just for TLD public announcement and/or publication, this deliberation is surely too long.
So it must be some better outcomes or finally over-delivery starting a new era for NWBio.
Based on my unwavering belief DCVax-L will be part of new Standard of Care for GBM within one year's time, I have accumulated about 258,000 shares in the last two weeks, including early today.
Plus sever figures of shares for long-term, with a great part well over the delivery of DCVax-D.
Trading for a few cents or dimes is not my style. So bring it on.
I expect the great quiet will be broke within a month or should I care if I am not trading?
Have to say my huge accumulated piles of shares is totally due to the failure of Linda Powers who has lengthened this process to unbearably long, but no doubt DCVax-L will be approved for GBM as a start.
net net no reason not to add shares at this low prices. One billion market cap to 10 billion market cap (10 beggars) may just be a few days or a week when thing happens.
To be fair, the current low price is perfectly aligned with general weakness of small biotech market (XBI as indicator), usual weakness of biotech sector after ASCO and of course the great quietness Linda self imposed, which is out-of-bound too long.
One or two factors above could change anytime, plus one or two dark horses may emerge, plus data will be announced, ...
Resuming buying soon, but have to say those recently bought shares will be used as a trade, not for a few cents/dimes of course.
And I have to add, when the price up with a few cents/dimes, most shares the manipulators MMs/hedges used in the manipulation will be recovered that why they are so bold to manipulate
always retail's loss at end, and Linda doesn't care, nor do I!
Dr. Richard Pazdur, Director of the FDA’s Oncology Center of Excellence said, "so I think the drug regulation will follow after we have effective therapies and the regulatory hurdles to getting a drug approved will be minimal really if these drugs are truly effective..."
Dr. Ned Sharpless, Director of the National Cancer Institute said, "doesn't look like progress at all until progress arrives, ......
my father died of metastatic melanoma in 2010. The first immunotherapy drug for metastatic melanin was approved in 2011. I can promise you in 2010 things looked pretty bleak for metastatic melanoma and that we has 30 years progress and lots of new therapies and lots of ideas but it didn't really pay off until about 12 months after my dad died so you know and now we cur,e cure, big c make the cancer go away never come back most patients with metastatic melanoma now just a mere less than 10 years later. so when the progress happens it can happen pretty quickly it doesn't look much is happening from the outside until we get there pretty quickly ......"
In the video, it talked about the confirmation of the very heterogeneity nature of GBM which calls for truly personalized approach; no meaningful progresses have been made in treating GBM over the last decades; CI as a class has seen successes in many indications in the past six to seven years particularly, but has shown no effects whatever when it is used in treating GBM in clinical trials.
And I consider it a good thing the discussion has no mentioning of vaccine treatment for obvious reason. And it seems while everyone involved look serious, FDA Pazdur is smiling all the time as if he know something others don't know.
One more genius Island boy so claimed
Poor Linda, Is that what you can only have at this time, even with a paradigm shift cancer treating vaccine platform for all solid tumors?
That only island boys would touch this baby?
plus the vast majority of retails who buy and sell for a couple of pennies or dimes?
I feel very sorry for the good product we have. DCVax you has been betrayed by humanity, but for how long I wonder.
So let the Island boys and their patron MMs to shift pathetic hundreds of shares each day among themselves during this Linda made quiet period.
I am detached from all of this. The only thing matters is dry powder.
That's a huge 35% short interest drop from 19,124,021 as of 30 June to 12,310,972 as of 15 July. Wow, shorts are smarter than those who have been thrown in the towel.
Manipulator MMs can fool only themselves by shifting shares among themselves.
Pitiful for those who have sold, and congratulation to those who have bought.
Next let those who have bought for swinging a couple of pennies or dimes to sell, and we will head up straight to new higher before TLD which could come right away after those who want to lock pittance of profit all have gone or switched back to sour grapes.
I have a midsummer dream which is beautiful.
From the below video, it confirms the very heterogeneity nature of GBM which calls for truly personalized approach; no meaningful progresses have been made in treating GBM over the decades; CI as a class has seen successes in many indication in the past six to seven years, but shown no effects when it is used in treating GBM.
It's good thing there has been no mentioning of vaccine treatment for obvious reason, and while everyone involved look serious as the deadly GBM is the subject, FDA Pazdur is smiling all the time as if he were on drug and feels high.
Title and video:
Conquer and Cure GBM: A #GBMDay Panel Discussion - National Brain Tumor Society
826 views
Streamed live on Jul 21, 2021
Absolutely agree on your statement, "Facts in the public domain. The rest is noise in the form of theories, deliberate scare tactics and misinformation"
It's the basis of fact of data known to the public from both DCVax-L trial and other trials for GBM, and the status of standards of care, combined with FDA's principle used in granting drug/agent approval that make a concrete DD leading to my decision to continually buy/add shares, all the way recently from $1.6s down.
GL
Excellent comments from a pro. Just add the following for both newbies and fudsters to ponder:
For the current standards of care:
Almost all patients experience tumor progression with nearly universal mortality and a median survival of less than 15 months from surgery, with a 2-year survival rate of 26–33%. To date, no new agents improve survival when added to standard therapy.
[source: https://www.ncbi.nlm.nih.gov/books/NBK469987/]
For the current DCVax-L P3 trial for GBM:
Population n Median OS since surgery Survival at 1 year Survival at 2 years Survival at 3 years
2017 data 331 23.1 months 89.3% 46.2% 25.4%
2018 data 331 23.1 months 89.3% 46.4% 28.2
[see as time goes by, the trend is that the OS has improved]
more detailed breakdown:
Data set n Median OS since surgery Survival at 1 year Survival at 2 years Survival at 3 years
2017 methylated 131 34.7 months 94.5% 66.7% 46.4%
2018 methylated 131 35.1 months 94.6% 66.6% 49.1%
2017 unmethylated 162 19.8 months 86.4% 32.1% 11.0%
2018 unmethylated 162 19.8 months 86.4% 32.6% 14.3
[source: https://nwbio.com/update-on-dc-vax-at-asco-2019/]
[Based on what we have know today as fact shown above, the odds of DCVax-L gained approved by FDA is substantially high (> 80%)]
Then, there is the current evolution version of FDA: Demonstrating Substantial Evidence of Effectiveness for Human Drug and
Biological Products Guidance for Industry -- https://www.fda.gov/media/133660/download]
and there is WHO's updated GBM definition which is highly in favor of DCVax-L's approval.
Finally, the principle for FDA to approve a new agent has always been the assessment of benefit-risk of the underlying agent. For DCVax-L, we know as fact it's safe almost without any side effects, so as long as nwbo can show concrete evidence that the vaccine is efficacious in treatment GBM, no regulatory agencies can deny its approval [a bit of rhetoric].
Thank you Senti. All the best!
I have posted right after CVM failed to meet its primary endpoint the fundamental difference between CVM and NWBO, and also thought CVM's agent Multikine should be approved for its safety and efficaciousness on those patients who are rightfully excluded from chemo treatment.
Simply put, CVM's agent Multikine is an immune booster which does not kill cancer cell while NWBO's agent DCVax-L is not only a booster but more importantly a cancer killer. Loaded with patient specific antigens, DCVax-L seeks, locates and kills remaining cancer.
That's a huge difference in MOAs, besides CVM has repeatedly failed using the same agent on other cancer indications while DCVax-L has never failed (actually it is on its first trial in phase 3).
CVM has experienced endless pumping from its own CEO while NWBO has been eerily quiet for a long time; CVM raised a significant amount of funds just before the announcement while NWBO has been running on fumes waiting TLD announcement.
gap up tomorrow for no reason
see you tomorrow done buying today
Understand your feeling. Actually biotech sector has been down for sometime, indicated by small biotech index xbi.
For nwbo, frustrated if you hold your shares, but happy if you add shares at this level.
btw, I sent Linda, Les a screen shot indicating share price manipulating subject: judiciary duty
I scooped a lot shares today, and happy (linda may not be happy seeing my email today)
regardless, I am a buyer at this range, and have bought recently all the way from $1.6s down.
Since I sold a house, I have "unlimited fund" at the time being LOL
bring it on
I don't think I am the only one who has added and has reached the "maximal numbers of shares" repeatedly which I never ever had expected a month or two ago, let lone many months or years ago.
It's never in my plan and it has broke my principal investment rule, but I am generally happy. Before each buying/adding more, I have refreshed my own DD, and each time I have gained more confidence.
So the problem is not why, but how much I can afford.
Now let me emphasize the conclusion I have come upon with each and every time:
IT'S MOST PROBABLE WHEN TLD IS DISCLOSED IT WILL SHOW BOTH THE PRIMARY AND KEY SECONDARY ENDPOINTS ARE SIGNIFICANT
and THE VACCINE IS SAFE WITH ALMOST NO SIDE EFFECTS!
How much better any investor can expect?
Resume buying this morning after a few days of pause, sensing manipulators MMs's algo would work at this convenient time for a couple of pennies of drop per day.
Sold a townhouse at this peak time [real estate], ready to put the proceed to crash the manipulator MMs.
I am ready, or to be honest have been ready for years, and most importantly the results will be glorious, safe and efficiouse, more than ready when revealed for RA approvals.
I know I read in the future NWBio's pivotal Ph3 trial of DCVax-L for GBM has met both its primary and key secondary endpoints in an unprecedentedly long, data rich stduy!
Not much more confidence one can have to not all in!
Exactly, why not hide behind it manipulating the price as naked short wolfpack?!
I have no problem with this because I keep average up and down, but would prefer Linda go after them when time is right.
And pretty much want to see justice has been served: these manipulating pigs get roasted!
About piglet OTCX according to OTC pig mom: [piglets octx and jane have spearheaded the current round of price manipulation for a while]
"The OTC Link ECN expands the depth of liquidity in OTC Securities by combining the Broker Dealer Network model with Anonymous, Auto-Execution functionality.
Access Greater Liquidity: Over 80% of non-internalized volume in OTC Securities occurs between OTC Link ATS subscribers
Fully Anonymous Orders: Provides anonymity through order, execution and clearing so that neither party is exposed
Auto-Ex Functionality: Improves the speed and real-time execution to meet the needs of OTC Equity Traders
Seamless Integration: Offers ECN subscribers the ability to enter orders through the Dealer user interface or via FIX connection
Cost Effective: Provides firms with an efficient solution to access liquidity with tiered pricing models
OTC Link ECN's aggregated top of book will be integrated with OTC Link ATS
Electronic order book functionality is provided by a low latency matching engine
Limit order book will include support for reserve orders
Automatic, anonymous routing to OTC Link ATS and other external destinations
Maker-Taker Pricing Model
Anti-internalization capabilities
https://www.otcmarkets.com/otc-link/otc-link-ecn
Piglets otcx and jane are on it again manipulating absence of news on the backdrop of cvm failure
They have been on it for quite some time, which stimulates me adding more shares.
Dave Innes efforts to persuade funds (particularly family funds)to be onboard have mostly failed so far, but things could change in a lightening speed for these funds which are currently on the sideline waiting for "de-risking" despite that kind of de-risking has been existing ever since 2018 publication and knowledge of how GBM has been treated and the decades-stagnation of treatment outcomes.
I can smell the taste of those piglets being roasted!
NWBio's P3 trial of DCVax-L for GBM has met its primary and secondary endpoints. The company has consulted with FDA and is seeking FDA's approval of DCVax-L for both nGBM and rGBM -- it will come, and may come any day!
I like roasted piglets
Not really. Short-term (a few days) impact of the failure of cvm on nwbo price - everybody has seen it now
med-term (within week) impact -- favorable for nwbo price appreciation
Long-term impact - none
only explain the first one - sympathy price drop understandable as most investors particularly non-investors who are considering and about to take a position are ignorant and have not done their DD yet. after some digging and digesting, actually those undecided or those who may be panic and sold some shares will finally realize
1) Multikine and DCVax-L are actually two different beasts
2) NWBio will be most likely meeting its primary and key secondary endpoints
3) the worst scenario for nwbo price drop if ever it would fail in its trial not meeting its primary endpoint like CVM is in the worst case 40%, not really that much expected by most investors
As a matter of fact, NWBio will probably meet its primary and key secondary endpoints
[conclusion:} new blood will flow into nwbo within days]
There is a huge and fundamental difference between cvm and nwbo in terms of MOA of cvm's failed Multikine and nwbo's dcvax-L.
Multikine is an immune booster designed to boost a patient's immune system before SOC treatment aimed to improve OS, quality of life, etc. just like grandma's chicken soup, while DCVax-L is not only an immune booster but more importantly "a cancer killing machine/system" loaded with patients' specific antigens, designed to seek, find and kill cancer cells.
CVM: CEO has constantly pumped the stock via social media and shareholder letters; the slim advantages (10% better than SOC) designed being very consistent to repeated failed previous trials for other indications (so aimed and fine-tuned to achieve "a lucky" success); one week before TLD a huge financing.
NWBO, CEO has behaved completely differently.
You buy nwbo -- a winning strategy
Don't touch cvm yet -- a winning strategy
[and Linda is dare enough to have dcvax trial results reviewed and analyzed by a panel of independent GBM experts!!!!]
[so the otcx pig is still on this one as of 9:38am 29 June]
agree, agree and agree
last post for me today, going to buy more if continual drifting low; already bought a lot at 1.50-1.52 range
GLA! we are close, very close
I can guarantee you the headline of nwbo's tld is nwbo's dcvax-L trial has met its primary endpoint
versus cvm's which avoided saying it has failed its primary endpoint, instead, cherry pick a subset.
logout and focus on buying more shares
CVM's failure is expected by many. The agent they tried Multikine has failed many times before for other cancer indication.
Despite its general failure for head and neck cancer, I do believe after all have settled down, they should get Multikine approved for those patients who receive Multikine followed by the part of SOC (surgery and radiotherapy only without chemo) because of reasonable improvement of OS plus quality of life for patients.
As for NWBO's DCVax-L, it's the first time DCVax-L is used in p3 clinical trial built up from positive p1/2 trial;
Most importantly, we know what the results would be look like from interim blinded, blended data published in 2018 on the backdrop of no improvement of SOC for GMB for decades and improvement data uptrend observed from the followed up data presentation after the publication.
Unless the final data readout is significantly worse than the data published in 2018 and/or placebo patients (or patients who received vaccine later after progression) outlive patients of treatment arm (or patients who received vaccine earlier before progression), it's no way DCVax-L will not show significant efficacy over SOC.
As I am typing, my first buy order is shown filled at 1.52. Intended to buy more as the price is artificially pulled down for obvious reason today: psychological impact for those ignorant due to CVM's failure, despite there is nothing comparable.
Besides, cvm ceo has spared no opportunities in pumping cvm stock while our dear ceo Linda has spared no opportunities keeping quiet.
[got a tiny order filled again at 1.51 as of 10:48am]
[Plus, cvm's large financing just last week or so was very suspicious]
[got this batch of order filled at 1.50]
[more to come]
Agreed, thank you and good luck to you too.
Not really. First, I for one believe there have been a naked short wolfpack who is one permanent force against this company and our collective interests;
Second, periodically, there are forces (not the same at one time) who want cheap shares and they will resort to bashing, FUD, etc.; and
Third, Market makers make money by making the market. Often than not, they would bring the price down, and accumulate which is the nature of market makers. So when a company openly say it is in a quiet period, it's a signal to market makers to bring down price.
At least, Linda has not committed a specific timeline which is desperately wanted by manipulators more than long-term investors.
At some time, these forces above act either coincidentally or not, results in depressed share price.
If you would ask me, when is the best time to buy or add more, I would say its when people are desperate and see no light ahead (in the near future) just like know.
years old. clue "in over 80% of the patients who have received DCVax in clinical trials to date"
Before data lock, around 90% of the patients had received DCVax in the clinical trials
There are always buyers who scooped up any shares sold. I am a buyer at $1.6s, $1.5s, and now you bet.
Initially want to sell some [other] stocks so that I can buy more here but the last minute I decided to take some money off my personal line of credit (byw at rates of around 2% -- kind of free money).
Here you go I am a buyer!
i will venture to say the company will release TLD as soon as it is ready, meaning the company may not time the release intentionally (as we believed in the past) to be close to publication/conference presentation and/or manufacturing certification.
the reason is that if the company has really been going through the process outlined in 5 October news release, which seems to be the case by now since the company has stressed it in the news release later and in accordance with what Linda has said at annual shareholder meeting.
In this sense, it seems the company will actually follow the conventional route of releasing TLD, followed by conference and publication.
Those six steps of process outlined in 5 October release, if followed through, will definitely guarantee high quality analyses of data and results, which will be proof against the usual nonsense, naysayers and innuendos.
So the time of TLD could really be any day from now, probably in July, followed by presentation of detailed results in ESMO in September.
Oh Danish Dude not that one. It looks innocent.